Applied Price To Sales Ratio vs Free Cash Flow Per Share Analysis

APDN Stock

USD 0.16 0.06 27.27%

Applied DNA financial indicator trend analysis is way more than just evaluating Applied DNA Sciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Applied DNA Sciences is a good investment. Please check the relationship between Applied DNA Price To Sales Ratio and its Free Cash Flow Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Applied DNA Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Price To Sales Ratio vs Free Cash Flow Per Share

Price To Sales Ratio vs Free Cash Flow Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Applied DNA Sciences Price To Sales Ratio account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Applied DNA's Price To Sales Ratio and Free Cash Flow Per Share is 0.15. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of Applied DNA Sciences, assuming nothing else is changed. The correlation between historical values of Applied DNA's Price To Sales Ratio and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Applied DNA Sciences are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of Price To Sales Ratio i.e., Applied DNA's Price To Sales Ratio and Free Cash Flow Per Share go up and down completely randomly.

Correlation Coefficient

0.15

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Applied DNA Sciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Applied DNA sales, a figure that is much harder to manipulate than other Applied DNA Sciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Most indicators from Applied DNA's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Applied DNA Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Applied DNA Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

As of the 15th of December 2024, Selling General Administrative is likely to drop to about 10 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 10.3 M

	2021	2022	2023	2024 (projected)
Total Revenue	18.2M	13.4M	15.4M	16.1M
Research Development	3.9M	3.7M	4.3M	4.5M

Total Revenue Research Development

Applied DNA fundamental ratios Correlations

	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Common Stock	Other Current Liab	Total Assets	Net Debt	Cash	Cash And Short Term Investments	Total Current Assets	Short Long Term Debt Total	Non Current Assets Total	Good Will	Intangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Non Currrent Assets Other	Property Plant And Equipment Gross	Short Term Debt	Net Receivables
Total Current Liabilities		0.43	-0.71	0.83	-0.53	0.38	0.39	0.72	0.73	-0.53	0.65	0.69	-0.44	0.59	0.59	0.58	0.41	0.56	0.53	0.58	0.58	0.34	0.39	0.48	-0.46	0.32
Total Stockholder Equity	0.43		-0.43	0.62	-0.2	0.24	0.11	0.43	0.27	-0.2	0.78	0.87	-0.85	0.76	0.76	0.9	0.04	0.48	0.32	0.68	0.54	0.01	0.48	0.36	-0.65	0.69
Retained Earnings	-0.71	-0.43		-0.7	0.26	-0.51	-0.5	-0.93	-0.67	0.26	-0.7	-0.65	0.46	-0.57	-0.57	-0.57	-0.51	-0.57	-0.61	-0.68	-0.64	-0.13	-0.17	-0.55	0.63	-0.17
Accounts Payable	0.83	0.62	-0.7		-0.35	0.32	0.3	0.63	0.59	-0.34	0.76	0.76	-0.63	0.67	0.67	0.78	0.27	0.48	0.5	0.63	0.56	0.17	0.44	0.41	-0.4	0.48
Common Stock Total Equity	-0.53	-0.2	0.26	-0.35		-0.2	-0.14	-0.29	-0.34	1.0	-0.42	-0.32	0.05	-0.15	-0.15	-0.22	0.26	-0.39	-0.08	-0.44	-0.3	-0.22	-0.28	-0.29	0.35	-0.22
Common Stock Shares Outstanding	0.38	0.24	-0.51	0.32	-0.2		0.86	0.7	0.79	-0.18	0.6	0.58	-0.43	0.6	0.6	0.29	-0.06	0.77	-0.03	0.76	0.83	-0.43	0.2	0.97	-0.3	-0.3
Non Current Liabilities Total	0.39	0.11	-0.5	0.3	-0.14	0.86		0.69	0.91	-0.13	0.46	0.55	-0.41	0.6	0.6	0.28	0.0	0.71	0.23	0.65	0.62	-0.24	0.22	0.86	-0.29	-0.3
Other Stockholder Equity	0.72	0.43	-0.93	0.63	-0.29	0.7	0.69		0.8	-0.29	0.71	0.72	-0.46	0.63	0.63	0.51	0.44	0.76	0.52	0.77	0.75	0.0	0.29	0.74	-0.65	0.08
Total Liab	0.73	0.27	-0.67	0.59	-0.34	0.79	0.91	0.8		-0.33	0.63	0.7	-0.5	0.7	0.7	0.47	0.15	0.77	0.41	0.73	0.71	-0.02	0.33	0.84	-0.39	-0.09
Common Stock	-0.53	-0.2	0.26	-0.34	1.0	-0.18	-0.13	-0.29	-0.33		-0.41	-0.31	0.04	-0.14	-0.14	-0.21	0.26	-0.38	-0.08	-0.43	-0.29	-0.23	-0.28	-0.28	0.35	-0.22
Other Current Liab	0.65	0.78	-0.7	0.76	-0.42	0.6	0.46	0.71	0.63	-0.41		0.9	-0.82	0.84	0.84	0.84	-0.02	0.61	0.37	0.92	0.84	-0.12	0.29	0.71	-0.61	0.35
Total Assets	0.69	0.87	-0.65	0.76	-0.32	0.58	0.55	0.72	0.7	-0.31	0.9		-0.88	0.92	0.92	0.9	0.11	0.74	0.44	0.87	0.76	-0.01	0.52	0.69	-0.68	0.46
Net Debt	-0.44	-0.85	0.46	-0.63	0.05	-0.43	-0.41	-0.46	-0.5	0.04	-0.82	-0.88		-0.96	-0.96	-0.93	-0.02	-0.39	-0.35	-0.68	-0.63	0.18	-0.21	-0.52	0.41	-0.35
Cash	0.59	0.76	-0.57	0.67	-0.15	0.6	0.6	0.63	0.7	-0.14	0.84	0.92	-0.96		1.0	0.88	0.11	0.55	0.4	0.75	0.74	-0.21	0.25	0.68	-0.42	0.2
Cash And Short Term Investments	0.59	0.76	-0.57	0.67	-0.15	0.6	0.6	0.63	0.7	-0.14	0.84	0.92	-0.96	1.0		0.88	0.11	0.55	0.4	0.75	0.74	-0.21	0.25	0.68	-0.42	0.2
Total Current Assets	0.58	0.9	-0.57	0.78	-0.22	0.29	0.28	0.51	0.47	-0.21	0.84	0.9	-0.93	0.88	0.88		0.07	0.4	0.45	0.69	0.59	0.09	0.32	0.42	-0.56	0.58
Short Long Term Debt Total	0.41	0.04	-0.51	0.27	0.26	-0.06	0.0	0.44	0.15	0.26	-0.02	0.11	-0.02	0.11	0.11	0.07		0.07	0.46	-0.12	-0.02	0.18	0.05	-0.11	-0.16	0.04
Non Current Assets Total	0.56	0.48	-0.57	0.48	-0.39	0.77	0.71	0.76	0.77	-0.38	0.61	0.74	-0.39	0.55	0.55	0.4	0.07		0.29	0.81	0.71	-0.12	0.71	0.82	-0.63	0.14
Good Will	0.53	0.32	-0.61	0.5	-0.08	-0.03	0.23	0.52	0.41	-0.08	0.37	0.44	-0.35	0.4	0.4	0.45	0.46	0.29		0.32	0.27	0.22	0.16	0.15	-0.4	0.27
Intangible Assets	0.58	0.68	-0.68	0.63	-0.44	0.76	0.65	0.77	0.73	-0.43	0.92	0.87	-0.68	0.75	0.75	0.69	-0.12	0.81	0.32		0.89	-0.13	0.42	0.86	-0.68	0.27
Property Plant And Equipment Net	0.58	0.54	-0.64	0.56	-0.3	0.83	0.62	0.75	0.71	-0.29	0.84	0.76	-0.63	0.74	0.74	0.59	-0.02	0.71	0.27	0.89		-0.29	0.16	0.91	-0.42	0.0
Current Deferred Revenue	0.34	0.01	-0.13	0.17	-0.22	-0.43	-0.24	0.0	-0.02	-0.23	-0.12	-0.01	0.18	-0.21	-0.21	0.09	0.18	-0.12	0.22	-0.13	-0.29		0.17	-0.37	-0.35	0.56
Non Currrent Assets Other	0.39	0.48	-0.17	0.44	-0.28	0.2	0.22	0.29	0.33	-0.28	0.29	0.52	-0.21	0.25	0.25	0.32	0.05	0.71	0.16	0.42	0.16	0.17		0.25	-0.54	0.55
Property Plant And Equipment Gross	0.48	0.36	-0.55	0.41	-0.29	0.97	0.86	0.74	0.84	-0.28	0.71	0.69	-0.52	0.68	0.68	0.42	-0.11	0.82	0.15	0.86	0.91	-0.37	0.25		-0.39	-0.18
Short Term Debt	-0.46	-0.65	0.63	-0.4	0.35	-0.3	-0.29	-0.65	-0.39	0.35	-0.61	-0.68	0.41	-0.42	-0.42	-0.56	-0.16	-0.63	-0.4	-0.68	-0.42	-0.35	-0.54	-0.39		-0.61
Net Receivables	0.32	0.69	-0.17	0.48	-0.22	-0.3	-0.3	0.08	-0.09	-0.22	0.35	0.46	-0.35	0.2	0.2	0.58	0.04	0.14	0.27	0.27	0.0	0.56	0.55	-0.18	-0.61

Click cells to compare fundamentals

Applied DNA Account Relationship Matchups

Applied DNA fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	4.3M	3.3M	4.2M	2.8M	3.3M	3.9M
Total Stockholder Equity	5.7M	11.1M	12.9M	5.0M	5.7M	6.0M
Retained Earnings	(269.8M)	(284.1M)	(292.5M)	(302.4M)	(272.2M)	(258.6M)
Accounts Payable	1.3M	1.4M	1.7M	1.1M	1.2M	892.3K
Common Stock Shares Outstanding	196.0K	345.9K	448.4K	653.8K	751.8K	789.4K
Non Current Liabilities Total	1.4M	31.5K	5.2M	5.9M	6.8M	7.2M
Other Stockholder Equity	275.5M	295.2M	305.4M	307.4M	353.5M	371.2M
Total Liab	5.6M	3.3M	9.4M	8.8M	10.1M	10.6M
Common Stock	5.1K	7.5K	12.9K	13.7K	12.3K	11.7K
Other Current Liab	676.4K	1.6M	1.9M	1.2M	1.1M	1.1M
Total Assets	11.3M	14.4M	22.3M	13.7M	15.7M	16.5M
Net Debt	(5.4M)	(6.6M)	(15.2M)	(5.9M)	(5.3M)	(5.1M)
Cash	7.8M	6.6M	15.2M	7.2M	8.2M	8.6M
Cash And Short Term Investments	7.8M	6.6M	15.2M	7.2M	8.2M	8.6M
Liabilities And Stockholders Equity	11.3M	14.4M	22.3M	13.7M	15.7M	16.5M
Total Current Assets	9.1M	11.3M	19.9M	8.1M	9.3M	5.0M
Non Current Assets Total	2.3M	3.1M	2.3M	5.5M	6.4M	6.7M
Intangible Assets	864.2K	734.8K	605.3K	2.7M	2.4M	2.6M
Property Plant And Equipment Net	1.3M	3.0M	2.2M	2.1M	2.4M	2.5M
Current Deferred Revenue	511.0K	281K	563.6K	76.4K	68.8K	65.4K
Non Currrent Assets Other	95.1K	95.0K	99.0K	750K	862.5K	905.6K
Property Plant And Equipment Gross	1.3M	3.8M	4.3M	5.5M	6.3M	6.6M
Net Receivables	194.3K	2.8M	3.1M	255.5K	293.8K	279.1K
Other Current Assets	1.2M	1.1M	2.1M	389.2K	447.6K	509.6K
Net Tangible Assets	(1.9M)	4.8M	11.1M	12.9M	14.8M	15.6M
Property Plant Equipment	226.2K	1.3M	3.0M	2.2M	2.6M	2.7M
Other Assets	172.0K	95.1K	95.0K	99.0K	89.1K	84.6K
Inventory	497.4K	1.4M	602.2K	330.0K	379.5K	347.2K
Other Liab	622.0K	848.3K	31.5K	5.2M	5.9M	6.2M

Pair Trading with Applied DNA

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Applied DNA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Applied DNA will appreciate offsetting losses from the drop in the long position's value.

Moving against Applied Stock

0.87	JBL	Jabil Circuit	Pair Corr
0.8	HPE	Hewlett Packard Ente	Pair Corr
0.74	CLS	Celestica Buyout Trend	Pair Corr
0.74	ZBRA	Zebra Technologies	Pair Corr
0.72	MSI	Motorola Solutions	Pair Corr

The ability to find closely correlated positions to Applied DNA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Applied DNA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Applied DNA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Applied DNA Sciences to buy it.

The correlation of Applied DNA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Applied DNA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Applied DNA Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Applied DNA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Applied DNA Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Applied DNA's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Applied Dna Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Applied Dna Sciences Stock:

How To Invest In Applied

Details

Is Applied Stock a good investment?

Details

What is Applied DNA's Net Worth?

Details

Largest Electronic Equipment, Instruments & Components Companies

View

Largest Technology Hardware & Equipment Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Applied DNA Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Is Electronic Equipment, Instruments & Components space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Applied DNA. If investors know Applied will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Applied DNA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(7.50)

Revenue Per Share

2.202

Quarterly Revenue Growth

(0.73)

Return On Assets

(0.57)

Return On Equity

(0.76)

The market value of Applied DNA Sciences is measured differently than its book value, which is the value of Applied that is recorded on the company's balance sheet. Investors also form their own opinion of Applied DNA's value that differs from its market value or its book value, called intrinsic value, which is Applied DNA's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Applied DNA's market value can be influenced by many factors that don't directly affect Applied DNA's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Applied DNA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Applied DNA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Applied DNA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Applied Price To Sales Ratio vs Free Cash Flow Per Share Analysis

Price To Sales Ratio vs Free Cash Flow Per Share

Price To Sales Ratio vs Free Cash Flow Per Share Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Free Cash Flow Per Share

Applied DNA fundamental ratios Correlations

Applied DNA Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Applied DNA fundamental ratios Accounts

Pair Trading with Applied DNA

Moving against Applied Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 0.97	Common Stock Shares Outstanding
Intangible Assets	+ 0.92	Other Current Liab
Cash	+ 0.92	Total Assets
Cash And Short Term Investments	+ 0.92	Total Assets

Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.96	Net Debt
Total Current Assets	- 0.93	Net Debt
Other Stockholder Equity	- 0.93	Retained Earnings
Net Debt	- 0.88	Total Assets
Net Debt	- 0.85	Total Stockholder Equity